GT200200115AA - Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion . - Google Patents

Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion .

Info

Publication number
GT200200115AA
GT200200115AA GT200200115AK GT200200115K GT200200115AA GT 200200115A A GT200200115A A GT 200200115AA GT 200200115A K GT200200115A K GT 200200115AK GT 200200115 K GT200200115 K GT 200200115K GT 200200115A A GT200200115A A GT 200200115AA
Authority
GT
Guatemala
Prior art keywords
procedure
preparation
pharmaceutical formulation
flavor
well
Prior art date
Application number
GT200200115AK
Other languages
English (en)
Inventor
Philippe Becourt
Josiani Chauvin
Detlev Schwabe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200200115AA publication Critical patent/GT200200115AA/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA FORMULACION FARMACEUTICA EN FORMA DE POLVO, DESTINADA A SER ADMINISTRADA EN SUSPENSION ACUOSA POR VIA ORAL, QUE ENMASCARA SU SABOR Y QUE INCLUYE POR LO MENOS UN POLIMERO CELULOSICO, UN POLIMERO METACRILICO Y UN PRINCIPIO ACTIVO DISTRIBUIDO DE MANERA HOMOGENEA Y EN ESTADO MOLECULAR EN UNA MATRIZ ATOMIZADA, ASI COMO UN AGENTE ALCALINO Y UN AGENTE ADSORBENTE, AL PROCEDIMIENTO PARA SU PREPARACION, ASI COMO A UN METODO DE ENMASCARAMIENTO DEL SABOR DE PRODUCTOS FARMACEUTICOS.
GT200200115AK 2001-06-21 2002-06-11 Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion . GT200200115AA (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0108157A FR2826274B1 (fr) 2001-06-21 2001-06-21 Formulation pharmaceutique au gout masque et son procede de preparation

Publications (1)

Publication Number Publication Date
GT200200115AA true GT200200115AA (es) 2005-01-12

Family

ID=8864587

Family Applications (2)

Application Number Title Priority Date Filing Date
GT200200115A GT200200115A (es) 2001-06-21 2002-06-11 Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion
GT200200115AK GT200200115AA (es) 2001-06-21 2002-06-11 Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion .

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GT200200115A GT200200115A (es) 2001-06-21 2002-06-11 Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion

Country Status (42)

Country Link
US (2) US7138138B2 (es)
EP (1) EP1401397B1 (es)
JP (1) JP4880871B2 (es)
CN (1) CN1239149C (es)
AP (1) AP1595A (es)
AR (1) AR036096A1 (es)
AT (1) ATE290366T1 (es)
AU (1) AU2002329311B2 (es)
BG (1) BG66314B1 (es)
BR (1) BRPI0208998A2 (es)
CA (1) CA2452239C (es)
CO (1) CO5540278A2 (es)
CZ (1) CZ299947B6 (es)
DE (1) DE60203178T2 (es)
EA (1) EA006016B1 (es)
EC (1) ECSP034915A (es)
ES (1) ES2236574T3 (es)
FR (1) FR2826274B1 (es)
GT (2) GT200200115A (es)
HK (1) HK1067558A1 (es)
HR (1) HRP20031067B1 (es)
HU (1) HUP0400799A3 (es)
IL (2) IL159404A0 (es)
JO (1) JO2325B1 (es)
MA (1) MA27042A1 (es)
MX (1) MXPA03011756A (es)
MY (1) MY134340A (es)
NO (1) NO332258B1 (es)
NZ (1) NZ530042A (es)
OA (1) OA12635A (es)
PA (1) PA8548301A1 (es)
PE (1) PE20030201A1 (es)
PL (1) PL202090B1 (es)
PT (1) PT1401397E (es)
SK (1) SK285865B6 (es)
SV (1) SV2003001098A (es)
TN (1) TNSN03141A1 (es)
TW (1) TWI228049B (es)
UA (1) UA77960C2 (es)
UY (1) UY27341A1 (es)
WO (1) WO2003000225A2 (es)
ZA (1) ZA200309479B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
GB2419094A (en) 2004-10-12 2006-04-19 Sandoz Ag Pharmaceutical composition of unpleasnt tasing active substances
FR2882522B1 (fr) * 2005-02-25 2007-04-13 Aventis Pharma Sa Composition pharmaceutique solide comprenant de la telithromycine
US7384922B2 (en) * 2005-05-04 2008-06-10 Enanta Pharmaceuticals, Inc. 6-11 bridged oxime erythromycin derivatives
US20060264386A1 (en) * 2005-05-17 2006-11-23 Rongqi Sun Pharmaceutical formulations of 6-11 bicyclic ketolide derivatives and related macrolides and methods for preparation thereof
KR101387249B1 (ko) * 2006-02-03 2014-05-21 에보니크 룀 게엠베하 물에 난용성인 유효 성분과 중합체의 혼합물을 함유하는제약 조성물
US20100226979A1 (en) * 2006-03-21 2010-09-09 Jubilant Organosys Limited Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate
US20080181932A1 (en) * 2007-01-30 2008-07-31 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
KR100935893B1 (ko) * 2007-09-11 2010-01-07 국방과학연구소 1,1'-다이메틸-5,5’-바이테트라졸의 합성방법
WO2009055557A1 (en) 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
WO2010069330A2 (en) 2008-12-16 2010-06-24 Carlsberg A/S Coating of hydroxylated surfaces by gas phase grafting
CA2868262A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
DE102012014848A1 (de) * 2012-07-27 2012-10-31 Heilerde-Gesellschaft Luvos Just GmbH & Co. KG Heilerde-Zubereitung
KR20170039689A (ko) * 2014-08-05 2017-04-11 셈프라 파마슈티컬스, 인크. 항균제의 분말 경구 현탁제 제형
CN114209661B (zh) * 2022-02-21 2022-04-29 北京罗诺强施医药技术研发中心有限公司 呈细粒形式的固体药物组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2930409A1 (de) * 1979-07-26 1981-02-12 Bayer Ag Spruehtrocknung von mikrokapseldispersionen
JPS63150220A (ja) * 1986-12-15 1988-06-22 Dainippon Pharmaceut Co Ltd 経口用固形製剤の製造方法
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
ZA945944B (en) * 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
EP1027036A2 (en) * 1997-10-03 2000-08-16 ELAN CORPORATION, Plc Taste masked formulations
IN191239B (es) * 1999-06-11 2003-10-11 Ranbaxy Lab Ltd
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
KR100502031B1 (ko) * 2000-08-22 2005-07-25 바실리어 파마슈티카 아게 항균 활성을 갖는 신규한 매크롤라이드

Also Published As

Publication number Publication date
CA2452239C (fr) 2011-07-19
UY27341A1 (es) 2003-01-31
AU2002329311B2 (en) 2007-02-01
HRP20031067A2 (en) 2004-04-30
HUP0400799A2 (hu) 2004-08-30
FR2826274B1 (fr) 2003-09-26
OA12635A (fr) 2006-06-15
US20070014857A1 (en) 2007-01-18
US20040142029A1 (en) 2004-07-22
IL159404A0 (en) 2004-06-01
BRPI0208998A2 (pt) 2017-06-06
PL202090B1 (pl) 2009-06-30
ZA200309479B (en) 2005-04-26
CZ20033441A3 (en) 2004-03-17
PL366803A1 (en) 2005-02-07
EA200400061A1 (ru) 2004-06-24
CN1529585A (zh) 2004-09-15
JO2325B1 (en) 2006-06-28
JP4880871B2 (ja) 2012-02-22
ATE290366T1 (de) 2005-03-15
IL159404A (en) 2007-08-19
JP2004534810A (ja) 2004-11-18
UA77960C2 (en) 2007-02-15
NO332258B1 (no) 2012-08-13
DE60203178D1 (de) 2005-04-14
BG66314B1 (bg) 2013-04-30
AR036096A1 (es) 2004-08-11
EA006016B1 (ru) 2005-08-25
MXPA03011756A (es) 2004-07-01
HUP0400799A3 (en) 2012-08-28
MY134340A (en) 2007-12-31
WO2003000225A3 (fr) 2003-03-13
EP1401397B1 (fr) 2005-03-09
AP2003002927A0 (en) 2003-12-31
HRP20031067B1 (en) 2011-10-31
SK285865B6 (sk) 2007-10-04
EP1401397A2 (fr) 2004-03-31
ECSP034915A (es) 2004-02-26
SK15922003A3 (sk) 2004-05-04
TWI228049B (en) 2005-02-21
CZ299947B6 (cs) 2009-01-07
CO5540278A2 (es) 2005-07-29
PA8548301A1 (es) 2003-09-05
NO20035581D0 (no) 2003-12-15
DE60203178T2 (de) 2006-01-26
AP1595A (en) 2006-04-12
BG108458A (bg) 2005-02-28
US7138138B2 (en) 2006-11-21
MA27042A1 (fr) 2004-12-20
SV2003001098A (es) 2003-03-18
PE20030201A1 (es) 2003-03-12
WO2003000225A2 (fr) 2003-01-03
NZ530042A (en) 2005-09-30
FR2826274A1 (fr) 2002-12-27
TNSN03141A1 (fr) 2005-12-23
CA2452239A1 (fr) 2003-01-03
CN1239149C (zh) 2006-02-01
GT200200115A (es) 2003-02-27
ES2236574T3 (es) 2005-07-16
HK1067558A1 (en) 2005-04-15
PT1401397E (pt) 2005-05-31

Similar Documents

Publication Publication Date Title
GT200200115AA (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion .
BR0112495A (pt) Forma de dosagem, processo para a produção de uma forma de dosagem e uso da forma de dosagem
BR0112054A (pt) Composição formadora de micelas, e métodos para a administração e a proteção de um agente terapêutico
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
AR029655A1 (es) Mejoras en formulaciones en pasta
BR0009604A (pt) Formulações de goma de mascar sobre-revestidas
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
NO20075136L (no) Nye liposompreparater
CR10838A (es) Derivados de 2,3-dihidroimidazol [1,2-c] quinazolina sustituidos, de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
WO2003035051A3 (en) The use of proton sequestering agents in drug formulations
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
MX2007006212A (es) Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular.
CL2007003331A1 (es) Metodo para tratar cancer mediante la administracion de un agente radiosensibilizante derivado de benzo[a]trinden-4,6-diona; composicion farmaceutica que comprende dicho agente.
BR0306501A (pt) Método para uso e produção de um tampão com medicamento
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada
AR024564A1 (es) Composicion que comprende esfingomielinasa para el uso como una preparacion dietetica, suplemento dietario o producto farmaceutico
PE20030323A1 (es) Composicion farmaceutica
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
ATE454136T1 (de) Therapeutische zusammensetzungen zur pulmonalen verabreichung
AR048050A1 (es) Formas de administracion masticables, no comprimidas, dosificadas individualmente
WO2008051527A3 (en) Sustained release of agents for localized pain management
AR047480A1 (es) Composicion para la prevencion y/o tratamiento de enfermedades metabolicas oseas; proceso de preparacion y uso de esta composicion
PE20050443A1 (es) Formulaciones farmaceuticas transdermicas